Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

home > ebr

PUBLICATIONS

European BioPharmaceutical Review

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:
Advertising Neil Clarke	Editorial Danielle Levett

	Subscribe
	Current Issue
	Archives
	Media Info
	Our Clients

Featured in this issue

BioBusiness Development
After the high-profile withdrawal of medicines with potentially fatal side effects, public concern over drug safety has reached a new level, and pharma companies must take this into consideration long before a product has been approved. William C Maier at REGISTRAT-MAPI explains the factors that affect risk perception, and suggests steps that can be taken to avoid negative media coverage.

BioBusiness Development
Strong lifecycle management has become more crucial than ever for maximising and exploiting a drug's potential during the years of market exclusivity; as Jan Hendrick Sitz and Markus Thunecke at Catenion point out, a therapeutic expansion strategy may be the solution for creating value and counteracting poor R&D productivity.

BioFinance and Management
The National Institute for Health and Clinical Excellence (NICE) in England and Wales has become the foremost appraiser of new medical technologies, although several of its decisions have been controversial. Joshua Cohen at the Tufts Center for the Study of Drug Development examines the NICE decision-making process and the impact it has had on the global pharmaceutical industry.

Edited by
Dr Helen Tayton-Martin,
Corporate & Business
Development Specialist,
Life Science

Published quarterly in
February, May,
August and November

Industry Events

P-MEC Europe

13-16 October 2009, Madrid, Spain

Hosted alongside CPhI, ICSE and BioPh, P-MEC (The Pharmaceutical Machinery and Equipment Convention) was first held in Madrid in 2005 and has since rapidly grown into a must-attend event for both sellers and buyers of pharmaceutical processing and manufacturing equipment. P-MEC has proven to be an invaluable new opportunity for exhibitors to meet new and existing clients, to find and approach new markets and to stay abreast of new developments in pharmaceutical manufacturing.
More info >>

All events >>

News and Press Releases

New Control Valve for Low Flowrates

Standard versions are available in DN 3 - 15 with Kv values from 63 - 3,300 l/h. The control characteristics are linear or equal-percentage depending on the regulating cone. Subsequent replacement of the regulating cone is possible at any time. A particular advantage is the hermetic separation between actuator and working medium by a sealing diaphragm which is available in EPDM or FPM and can easily be replaced.
More info >>

All releases >>

Air Transport Publications